Hydroxychloroquine in Individuals At-risk for Type 1 Diabetes Mellitus
Status:
Recruiting
Trial end date:
2024-08-01
Target enrollment:
Participant gender:
Summary
The study is a 2-arm, double blinded, multicenter, 2:1 randomized, placebo controlled
clinical trial. Subjects will receive hydroxychloroquine or placebo and close monitoring for
progression of T1D.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)